Confirmed Exhibitors
Advertising & Exhibits > Confirmed Exhibitors

Advertising & Exhibits
IASLC’s annual World Conference on Lung Cancer has played an integral part in facilitating progress by providing a platform for sharing cutting-edge research, collaboration, and networking among industry leaders, experts, and visionaries from around the world.
We’re thrilled to showcase the incredible companies and organizations that will join us in the Exhibit Hall for this year’s conference. Each logo below is a doorway to discovering innovative products, services, and ideas. Take a moment to click on the logos and learn more about what they stand for.
Start exploring now!
WCLC 2025 Exhibitors:

AbbVie Oncology

Accord Healthcare

ALCMI

American Association For Cancer Research (AACR)

Amgen

AstraZeneca

Bayer

Boehringer Ingelheim

Catalyst Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Eli Lilly and Company

Genmab

Gilead Oncology

Gradiant Bioconvergence (GBCC)

Johnson & Johnson

Median Technologies

Nuvation Bio

Pfizer Oncology

PharmaMar

Regeneron

Roche

Scanlan International

AbbVie Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody, and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Accord Healthcare
Headquartered in the United Kingdom, Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care. Our approach is agile and inventive, we’re driven to think differently by continuing to explore and deliver high quality medicines designed to benefit patients’ lives worldwide.

ALCMI
ALCMI is a nonprofit international consortium comprised of 25 of the world’s premier oncology research institutions. We partner with the top minds from the most respected medical facilities, providing financial support and access to a team of experts and staff to assist in launching and managing investigator-initiated trials. We bridge the gap between clinical research organizations (CROs) and site management organizations (SMOs), resulting in a streamlined, agile process for quickly funding and initiating lung cancer research projects.

American Association For Cancer Research (AACR)
The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through: Research, Education, Communication, Collaboration, Science Policy and Advocacy, and Funding for Cancer Research. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Amgen
Amgen harnesses the best of biology and technology to make people’s lives easier, fuller and longer. We draw upon our deep knowledge of science to push beyond what’s known today. With roots in the biotech revolution, we are one of the world’s leading independent biotech companies.

AstraZeneca
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to deliver life-changing medicines to patients.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

Bayer
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise includes both marketed products and clinical development compounds, which reflect the company’s approach to research: prioritizing targets and pathways with the potential to impact the way that cancer is treated.

Boehringer Ingelheim
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research.

Catalyst Pharmaceuticals, Inc.
Catalyst is committed to developing and commercializing novel medicines for patients living with rare and difficult to treat neurological diseases.

Daiichi Sankyo, Inc.
With more than 120 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.

Eli Lilly and Company
Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer and other serious diseases. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Gilead Oncology
Gilead Oncology is working to transform how cancer is treated. We are innovating with next generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody drug conjugates and small molecules to cell therapy based approaches, we are creating new possibilities for people with cancer.

Gradiant Bioconvergence (GBCC)
Gradiant Bioconvergence (GBCC) is an organization developing patient-derived cancer organoids (PDOs) in a global scale. We have built Asia’s largest repository of PDOs with next-generation sequencing of over 700 models from patients with lung, gastric, colorectal, pancreas, and ovarian cancer. In addition, we are developing co-culture systems with autologous immune cells. Our PDO models are available for drug evaluation services. Based on our genomic and drug response data, we are discovering and validating novel oncology targets through our AI-driven target discovery and CRISPR-based PDO platform. Beyond cancer, GBCC has established brain organoids from hiPSCs for drug evaluation and disease modeling.

Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.”

Median Technologies
Pioneering innovative imaging services and Software as Medical Devices, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as medical devices (SaMD) for the early diagnosis of lung and liver cancers. Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies.

Nuvation Bio
Nuvation Bio is a late clinical-stage, global biopharmaceutical company focused on treating patients with the most difficult-to-treat cancers for which conventional therapies have failed.

Pfizer Oncology
Pfizer Oncology is at the forefront of a new era in cancer care. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives

PharmaMar
PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center.

Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
Roche is also the world leader in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. For more information, please visit roche.com.

Scanlan International
Since 1921, the Scanlan family has been dedicated to hand-crafting the world’s finest surgical instruments. Explore our Scanlan® LEGACY Needle Holders and Forceps, showcasing the revolutionary Scan-II™ handle design. Our comprehensive range includes Scanlan® VATS instruments such as D’Amico Clamps, Suctions, Biopsy Forceps, Gonzalez-Rivas Dissector, Rocco Nodule Clamps, and Khan Decortication Grasper. Join us on our continued journey of excellence in surgical solutions.